{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T15:22:09Z","timestamp":1795188129575,"version":"4.10.3"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutations in glucocerebrosidase cause the lysosomal storage disorder Gaucher\u2019s disease and are the most common risk factor for Parkinson\u2019s disease. Therapies to restore the enzyme\u2019s function in the brain hold great promise for treating the neurological implications. Thus, we developed blood-brain barrier penetrant therapeutic molecules by fusing transferrin receptor-binding moieties to \u03b2-glucocerebrosidase (referred to as GCase-BS). We demonstrate that these fusion proteins show significantly increased uptake and lysosomal efficiency compared to the enzyme alone. In a cellular disease model, GCase-BS rapidly rescues the lysosomal proteome and lipid accumulations beyond known substrates. In a mouse disease model, intravenous injection of GCase-BS leads to a sustained reduction of glucosylsphingosine and can lower neurofilament-light chain plasma levels. Collectively, these findings demonstrate the potential of GCase-BS for treating\n                    <jats:italic>GBA1<\/jats:italic>\n                    -associated lysosomal dysfunction, provide insight into candidate biomarkers, and may ultimately open a promising treatment paradigm for lysosomal storage diseases extending beyond the central nervous system.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-37632-4","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T05:03:45Z","timestamp":1681275825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Targeting neuronal lysosomal dysfunction caused by \u03b2-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-7316","authenticated-orcid":false,"given":"Alexandra","family":"Gehrlein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-0649","authenticated-orcid":false,"given":"Vinod","family":"Udayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Anastasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-1698","authenticated-orcid":false,"given":"Martino L.","family":"Morella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Brugger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"von der Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Rufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Heer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Pfahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Jochner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Niewoehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Fueth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0361-4636","authenticated-orcid":false,"given":"Martin","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Villase\u00f1or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Ehsaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-5976","authenticated-orcid":false,"given":"Verdon","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Sidransky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6897-5558","authenticated-orcid":false,"given":"David J.","family":"Vocadlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Ola","family":"Freskg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-7643","authenticated-orcid":false,"given":"Ravi","family":"Jagasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"37632_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","volume":"1793","author":"T Braulke","year":"2009","unstructured":"Braulke, T. & Bonifacino, J. S. Sorting of lysosomal proteins. Biochim. Et. Biophys. Acta Bba - Mol. Cell Res. 1793, 605\u2013614 (2009).","journal-title":"Biochim. Et. Biophys. Acta Bba - Mol. Cell Res."},{"key":"37632_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","volume":"9","author":"R-MN Boustany","year":"2013","unstructured":"Boustany, R.-M. N. Lysosomal storage diseases\u2014the horizon expands. Nat. Rev. Neurol. 9, 583\u2013598 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"37632_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","volume":"76","author":"E Orvisky","year":"2002","unstructured":"Orvisky, E. et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol. Genet. Metab. 76, 262\u2013270 (2002).","journal-title":"Mol. Genet. Metab."},{"key":"37632_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/0005-2760(82)90272-7","volume":"712","author":"O Nilsson","year":"1982","unstructured":"Nilsson, O., M\u00e5nsson, J.-E., H\u00e5kansson, G. & Svennerholm, L. The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of gaucher\u2019s disease. Biochim. Et. Biophys. Acta Bba - Lipids Lipid Metab. 712, 453\u2013463 (1982).","journal-title":"Biochim. Et. Biophys. Acta Bba - Lipids Lipid Metab."},{"key":"37632_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/1873-3468.12104","volume":"590","author":"MJ Ferraz","year":"2016","unstructured":"Ferraz, M. J. et al. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases. Febs. Lett. 590, 716\u2013725 (2016).","journal-title":"Febs. Lett."},{"key":"37632_CR6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/jcm9030736","volume":"9","author":"DEC Boer","year":"2020","unstructured":"Boer, D. E. C., van Smeden, J., Bouwstra, J. A. & Aerts, J. M. F. G. Glucocerebrosidase: functions in and beyond the lysosome. J. Clin. Med. 9, 736 (2020).","journal-title":"J. Clin. Med."},{"key":"37632_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuron.2017.01.018","volume":"93","author":"E Aflaki","year":"2017","unstructured":"Aflaki, E., Westbroek, W. & Sidransky, E. The complicated relationship between gaucher disease and parkinsonism: insights from a rare disease. Neuron 93, 737\u2013746 (2017).","journal-title":"Neuron"},{"key":"37632_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","volume":"114","author":"K Weiss","year":"2015","unstructured":"Weiss, K. et al. The clinical management of type 2 Gaucher disease. Mol. Genet. Metab. 114, 110\u2013122 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"37632_CR9","doi-asserted-by":"publisher","first-page":"e2119","DOI":"10.1212\/WNL.0000000000010605","volume":"95","author":"TR Lal","year":"2020","unstructured":"Lal, T. R. et al. The natural history of type 2 Gaucher disease in the 21st century: a retrospective study. Neurology 95, e2119\u2013e2130 (2020).","journal-title":"Neurology"},{"key":"37632_CR10","unstructured":"Beutler, E. and Grabowski, GA. Gaucher disease. In the metabolic and molecular basis of inherited disease (eds. Scriver, C.R., Beaudet, A.L., Sly, W.S. and Vogelstein, D.) 3635\u20133668 (McGraw-Hill, New York, 2001)."},{"key":"37632_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/diseases5010010","volume":"5","author":"TR Lal","year":"2017","unstructured":"Lal, T. R. & Sidransky, E. The spectrum of neurological manifestations associated with Gaucher disease. Diseases 5, 10 (2017).","journal-title":"Diseases"},{"key":"37632_CR12","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","volume":"11","author":"E Sidransky","year":"2012","unstructured":"Sidransky, E. & Lopez, G. The link between the GBA gene and parkinsonism. Lancet Neurol. 11, 986\u2013998 (2012).","journal-title":"Lancet Neurol."},{"key":"37632_CR13","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ana.24781","volume":"80","author":"G Liu","year":"2016","unstructured":"Liu, G. et al. Specifically neuropathic Gaucher\u2019s mutations accelerate cognitive decline in Parkinson\u2019s. Ann. Neurol. 80, 674\u2013685 (2016).","journal-title":"Ann. Neurol."},{"key":"37632_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/jnc.13385","volume":"139","author":"A Migdalska\u2010Richards","year":"2016","unstructured":"Migdalska\u2010Richards, A. & Schapira, A. H. V. The relationship between glucocerebrosidase mutations and Parkinson disease. J. Neurochem. 139, 77\u201390 (2016).","journal-title":"J. Neurochem."},{"key":"37632_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-019-0339-z","volume":"14","author":"M Huebecker","year":"2019","unstructured":"Huebecker, M. et al. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson\u2019s disease. Mol. Neurodegener. 14, 40 (2019).","journal-title":"Mol. Neurodegener."},{"key":"37632_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1203\/00006450-200008000-00018","volume":"48","author":"E Orvisky","year":"2000","unstructured":"Orvisky, E. et al. Glucosylsphingosine accumulation in mice and patients with Type 2 Gaucher disease begins early in gestation. Pediatr. Res. 48, 233\u2013237 (2000).","journal-title":"Pediatr. Res."},{"key":"37632_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.cbpa.2019.10.006","volume":"53","author":"JMFG Aerts","year":"2019","unstructured":"Aerts, J. M. F. G. et al. Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease. Curr. Opin. Chem. Biol. 53, 204\u2013215 (2019).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"37632_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jnr.490180206","volume":"18","author":"JB Fishman","year":"1987","unstructured":"Fishman, J. B., Rubin, J. B., Handrahan, J. V., Connor, J. R. & Fine, R. E. Receptor\u2010mediated transcytosis of transferrin across the blood\u2010brain barrier. J. Neurosci. Res. 18, 299\u2013304 (1987).","journal-title":"J. Neurosci. Res."},{"key":"37632_CR19","doi-asserted-by":"publisher","first-page":"H1149","DOI":"10.1152\/ajpheart.1996.270.4.H1149","volume":"270","author":"L Descamps","year":"1996","unstructured":"Descamps, L., Dehouck, M. P., Torpier, G. & Cecchelli, R. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am. J. Physiol.-Heart C 270, H1149\u2013H1158 (1996).","journal-title":"Am. J. Physiol.-Heart C"},{"key":"37632_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20131660","volume":"211","author":"N Bien-Ly","year":"2014","unstructured":"Bien-Ly, N. et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J. Exp. Med. 211, 233\u2013244 (2014).","journal-title":"J. Exp. Med."},{"key":"37632_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"Niewoehner, J. et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49\u201360 (2014).","journal-title":"Neuron"},{"key":"37632_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JBB Ridgway","year":"1996","unstructured":"Ridgway, J. B. B., Presta, L. G. & Carter, P. \u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. Des. Sel. 9, 617\u2013621 (1996).","journal-title":"Protein Eng. Des. Sel."},{"key":"37632_CR23","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1073\/pnas.1818411116","volume":"116","author":"R Romero","year":"2019","unstructured":"Romero, R. et al. Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning. Proc. Natl. Acad. Sci. 116, 5086\u20135095 (2019).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"37632_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1432-1033.1985.tb08655.x","volume":"146","author":"AM Vaccaro","year":"1985","unstructured":"Vaccaro, A. M., Muscillo, M. & Suzuki, K. Characterization of human glucosylsphingosine glucosyl hydrolase and comparison with glucosylceramidase. Eur. J. Biochem. 146, 315\u2013321 (1985).","journal-title":"Eur. J. Biochem."},{"key":"37632_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/oxfordjournals.jbchem.a124284","volume":"115","author":"N Sasagasako","year":"1994","unstructured":"Sasagasako, N., Kobayashi, T., Yamaguchi, Y., Shinnoh, N. & Goto, I. Glucosylceramide and glucosylsphingosine metabolism in cultured fibroblasts deficient in Acid \u03b2-glucosidase activity. J. Biochem. 115, 113\u2013119 (1994).","journal-title":"J. Biochem."},{"key":"37632_CR26","first-page":"769","volume":"9","author":"W Westbroek","year":"2016","unstructured":"Westbroek, W. et al. A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease. Dis. Model Mech. 9, 769\u2013778 (2016).","journal-title":"Dis. Model Mech."},{"key":"37632_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.scr.2017.07.009","volume":"23","author":"AL G\u00fcndner","year":"2017","unstructured":"G\u00fcndner, A. L. et al. Generation of a homozygous GBA deletion human embryonic stem cell line. Stem Cell Res. 23, 122\u2013126 (2017).","journal-title":"Stem Cell Res."},{"key":"37632_CR28","doi-asserted-by":"publisher","first-page":"e0252325","DOI":"10.1371\/journal.pone.0252325","volume":"16","author":"NK Polinski","year":"2021","unstructured":"Polinski, N. K. et al. Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model. Plos One 16, e0252325 (2021).","journal-title":"Plos One"},{"key":"37632_CR29","doi-asserted-by":"publisher","first-page":"e2200553119","DOI":"10.1073\/pnas.2200553119","volume":"119","author":"MC Deen","year":"2022","unstructured":"Deen, M. C. et al. A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells. Proc. Natl. Acad. Sci. 119, e2200553119 (2022).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"37632_CR30","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1098\/rstb.2003.1269","volume":"358","author":"RO Brady","year":"2003","unstructured":"Brady, R. O. Enzyme replacement therapy: conception, chaos and culmination. Philos. Trans. Royal Soc. Lond. Ser B Biol. Sci. 358, 915\u2013919 (2003).","journal-title":"Philos. Trans. Royal Soc. Lond. Ser B Biol. Sci."},{"key":"37632_CR31","unstructured":"Rasmussen, J., Barsomian, G. & Bergh, M. Enzymatically active recombinant glucocerebrosidase. US Pat. Appl. 08\/442,603, filed May 17, 1995, issued Sep. 17, 2002. Patent No. US 6,451,600 B1."},{"key":"37632_CR32","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1038\/s41598-017-05633-1","volume":"7","author":"S Fedele","year":"2017","unstructured":"Fedele, S. et al. Expansion of human midbrain floor plate progenitors from induced pluripotent stem cells increases dopaminergic neuron differentiation potential. Sci. Rep.-U.K. 7, 6036 (2017).","journal-title":"Sci. Rep.-U.K."},{"key":"37632_CR33","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1016\/j.jmb.2020.04.002","volume":"432","author":"ZR Crook","year":"2020","unstructured":"Crook, Z. R. et al. A TfR-binding cystine-dense peptide promotes blood\u2013brain barrier penetration of bioactive molecules. J. Mol. Biol. 432, 3989\u20134009 (2020).","journal-title":"J. Mol. Biol."},{"key":"37632_CR34","doi-asserted-by":"publisher","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","volume":"3","author":"YJ Yu","year":"2011","unstructured":"Yu, Y. J. et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 3, 84ra44\u201384ra44 (2011).","journal-title":"Sci. Transl. Med."},{"key":"37632_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","volume":"570","author":"H Mathys","year":"2019","unstructured":"Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer\u2019s disease. Nature 570, 332\u2013337 (2019).","journal-title":"Nature"},{"key":"37632_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/glycob\/cwm008","volume":"17","author":"SMV Patten","year":"2007","unstructured":"Patten, S. M. V. et al. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 17, 467\u2013478 (2007).","journal-title":"Glycobiology"},{"key":"37632_CR37","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1126\/science.aan6298","volume":"358","author":"M Abu-Remaileh","year":"2017","unstructured":"Abu-Remaileh, M. et al. Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes. Science 358, 807\u2013813 (2017).","journal-title":"Science"},{"key":"37632_CR38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.tcb.2017.07.006","volume":"27","author":"AM Thelen","year":"2017","unstructured":"Thelen, A. M. & Zoncu, R. Emerging roles for the lysosome in lipid metabolism. Trends Cell Biol. 27, 833\u2013850 (2017).","journal-title":"Trends Cell Biol."},{"key":"37632_CR39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1021\/acs.jproteome.9b00580","volume":"19","author":"J Singh","year":"2020","unstructured":"Singh, J. et al. Systematic comparison of strategies for the enrichment of lysosomes by data independent acquisition. J. Proteome Res. 19, 371\u2013381 (2020).","journal-title":"J. Proteome Res."},{"key":"37632_CR40","doi-asserted-by":"publisher","first-page":"7972","DOI":"10.3390\/ijms22157972","volume":"22","author":"Z Toleikis","year":"2021","unstructured":"Toleikis, Z. et al. S100A9 alters the pathway of alpha-synuclein amyloid aggregation. Int. J. Mol. Sci. 22, 7972 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"37632_CR41","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12974-018-1210-9","volume":"15","author":"I Horvath","year":"2018","unstructured":"Horvath, I. et al. Co-aggregation of pro-inflammatory S100A9 with \u03b1-synuclein in Parkinson\u2019s disease: ex vivo and in vitro studies. J. Neuroinflamm 15, 172 (2018).","journal-title":"J. Neuroinflamm"},{"key":"37632_CR42","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/hmg\/ddq550","volume":"20","author":"Y Ren","year":"2011","unstructured":"Ren, Y., Jiang, H., Ma, D., Nakaso, K. & Feng, J. Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases. Hum. Mol. Genet. 20, 1074\u20131083 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"37632_CR43","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1194\/jlr.M500202-JLR200","volume":"46","author":"Y Sun","year":"2005","unstructured":"Sun, Y., Quinn, B., Witte, D. P. & Grabowski, G. A. Gaucher disease mouse models: point mutations at the acid \u03b2-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J. Lipid Res. 46, 2102\u20132113 (2005).","journal-title":"J. Lipid Res."},{"key":"37632_CR44","doi-asserted-by":"publisher","first-page":"e0227077","DOI":"10.1371\/journal.pone.0227077","volume":"15","author":"V Schiffer","year":"2020","unstructured":"Schiffer, V. et al. Characterization of the visceral and neuronal phenotype of 4L\/PS-NA mice modeling Gaucher disease. Plos One 15, e0227077 (2020).","journal-title":"Plos One"},{"key":"37632_CR45","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fnins.2020.00579","volume":"14","author":"T Loeffler","year":"2020","unstructured":"Loeffler, T., Schilcher, I., Flunkert, S. & Hutter-Paier, B. Neurofilament-light chain as biomarker of neurodegenerative and rare diseases with high translational value. Front. Neurosci. Switz. 14, 579 (2020).","journal-title":"Front. Neurosci. Switz."},{"key":"37632_CR46","doi-asserted-by":"publisher","unstructured":"Udayar, V., Chen, Y., Sidransky, E. & Jagasia, R. Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. Trends Neurosci. https:\/\/doi.org\/10.1016\/j.tins.2021.12.004 (2022).","DOI":"10.1016\/j.tins.2021.12.004"},{"key":"37632_CR47","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrm1423","volume":"5","author":"AH Futerman","year":"2004","unstructured":"Futerman, A. H. & van Meer, G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Bio. 5, 554\u2013565 (2004).","journal-title":"Nat. Rev. Mol. Cell Bio."},{"key":"37632_CR48","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1055\/s-2005-872810","volume":"36","author":"B Hoffmann","year":"2005","unstructured":"Hoffmann, B. & Mayatepek, E. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities. Neuropediatrics 36, 285\u2013289 (2005).","journal-title":"Neuropediatrics"},{"key":"37632_CR49","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1073\/pnas.1220464110","volume":"110","author":"SP Sardi","year":"2013","unstructured":"Sardi, S. P. et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl. Acad. Sci. 110, 3537\u20133542 (2013).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"37632_CR50","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s40263-020-00746-0","volume":"34","author":"E Menozzi","year":"2020","unstructured":"Menozzi, E. & Schapira, A. H. V. Enhancing the activity of glucocerebrosidase as a treatment for parkinson disease. Cns Drugs 34, 915\u2013923 (2020).","journal-title":"Cns Drugs"},{"key":"37632_CR51","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","volume":"113","author":"NJ Weinreb","year":"2002","unstructured":"Weinreb, N. J. et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med. 113, 112\u2013119 (2002).","journal-title":"Am. J. Med."},{"key":"37632_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski, G. A. et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122, 33 (1995).","journal-title":"Ann. Intern. Med."},{"key":"37632_CR53","doi-asserted-by":"publisher","first-page":"eaay1163","DOI":"10.1126\/scitranslmed.aay1163","volume":"12","author":"JC Ullman","year":"2020","unstructured":"Ullman, J. C. et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci. Transl. Med. 12, eaay1163 (2020).","journal-title":"Sci. Transl. Med."},{"key":"37632_CR54","doi-asserted-by":"publisher","first-page":"eaay1359","DOI":"10.1126\/scitranslmed.aay1359","volume":"12","author":"MS Kariolis","year":"2020","unstructured":"Kariolis, M. S. et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci. Transl. Med. 12, eaay1359 (2020).","journal-title":"Sci. Transl. Med."},{"key":"37632_CR55","first-page":"332","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. Blood\u2013brain barrier-traversing biologic secures regulatory approval, in Japan. Nat. Rev. Drug Discov. 20, 332\u2013332 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"37632_CR56","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","volume":"26","author":"H Sonoda","year":"2018","unstructured":"Sonoda, H. et al. A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol. Ther. 26, 1366\u20131374 (2018).","journal-title":"Mol. Ther."},{"key":"37632_CR57","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1016\/j.cell.2021.08.002","volume":"184","author":"T Logan","year":"2021","unstructured":"Logan, T. et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell 184, 4651\u20134668.e25 (2021).","journal-title":"Cell"},{"key":"37632_CR58","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton, N. W. et al. Replacement therapy for inherited enzyme deficiency \u2014 macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N. Engl. J. Med. 324, 1464\u20131470 (1991).","journal-title":"N. Engl. J. Med."},{"key":"37632_CR59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nrm1050","volume":"4","author":"P Ghosh","year":"2003","unstructured":"Ghosh, P., Dahms, N. M. & Kornfeld, S. Mannose 6-phosphate receptors: new twists in the tale. Nat. Rev. Mol. Cell Biol. 4, 202\u2013213 (2003).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"37632_CR60","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1055\/s-2007-978725","volume":"31","author":"T Braulke","year":"1999","unstructured":"Braulke, T. Type-2 IGF receptor: a multi-ligand binding protein. Horm. Metab. Res. 31, 242\u2013246 (1999).","journal-title":"Horm. Metab. Res."},{"key":"37632_CR61","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","volume":"15","author":"L Kohler","year":"2018","unstructured":"Kohler, L., Puertollano, R. & Raben, N. Pompe disease: from basic science to therapy. Neurotherapeutics 15, 928\u2013942 (2018).","journal-title":"Neurotherapeutics"},{"key":"37632_CR62","unstructured":"Benz, J., Ebeling, M., Jagasia, R., Pfahler, N. & Thoma, R. Glucocerebrosidase mutants. US Pat. Appl. 17\/641,740, filed Sep. 7, 2020, issued Oct. 13, 2022. Patent No. US 2022\/0325265 A1."},{"key":"37632_CR63","unstructured":"Do, H. Variant, recombinant beta-glucocerebrosidase protein with increased stability and increased retained catalytic activity. US Pat. Appl. 15\/430,682, filed Feb. 13, 2017, issued Nov. 21, 2017. Patent No. US 9,821,038 B2."},{"key":"37632_CR64","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/mt.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti, G., Andria, G. & Valenzano, K. J. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol. Ther. 23, 1138\u20131148 (2015).","journal-title":"Mol. Ther."},{"key":"37632_CR65","doi-asserted-by":"publisher","first-page":"e125358","DOI":"10.1172\/jci.insight.125358","volume":"4","author":"S Xu","year":"2019","unstructured":"Xu, S. et al. Improved efficacy of a next-generation ERT in murine Pompe disease. Jci Insight 4, e125358 (2019).","journal-title":"Jci Insight"},{"key":"37632_CR66","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fcell.2020.00271","volume":"8","author":"T-U Han","year":"2020","unstructured":"Han, T.-U., Sam, R. & Sidransky, E. Small molecule chaperones for the treatment of Gaucher disease and GBA1-associated parkinson disease. Front. Cell Dev. Biol. 8, 271 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"37632_CR67","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.tins.2019.05.010","volume":"42","author":"T Farfel-Becker","year":"2019","unstructured":"Farfel-Becker, T., Do, J., Tayebi, N. & Sidransky, E. Can GBA1-associated parkinson disease be modeled in the mouse? Trends Neurosci. 42, 631\u2013643 (2019).","journal-title":"Trends Neurosci."},{"key":"37632_CR68","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ymgme.2012.04.024","volume":"106","author":"RJ Tamargo","year":"2012","unstructured":"Tamargo, R. J., Velayati, A., Goldin, E. & Sidransky, E. The role of saposin C in Gaucher disease. Mol. Genet. Metab. 106, 257\u2013263 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"37632_CR69","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.molmed.2020.07.004","volume":"26","author":"N Tayebi","year":"2020","unstructured":"Tayebi, N., Lopez, G., Do, J. & Sidransky, E. Pro-cathepsin D, prosaposin, and progranulin: lysosomal networks in parkinsonism. Trends Mol. Med. 26, 913\u2013923 (2020).","journal-title":"Trends Mol. Med."},{"key":"37632_CR70","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cpdd.865","volume":"10","author":"MJ Peterschmitt","year":"2021","unstructured":"Peterschmitt, M. J. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers. Clin. Pharm. Drug Dev. 10, 86\u201398 (2021).","journal-title":"Clin. Pharm. Drug Dev."},{"key":"37632_CR71","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.27414","volume":"33","author":"SP Sardi","year":"2018","unstructured":"Sardi, S. P., Cedarbaum, J. M. & Brundin, P. Targeted therapies for parkinson\u2019s disease: from genetics to the clinic. Mov. Disord 33, 684\u2013696 (2018).","journal-title":"Mov. Disord"},{"key":"37632_CR72","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.celrep.2016.02.090","volume":"15","author":"V Costa","year":"2016","unstructured":"Costa, V. et al. mTORC1 inhibition corrects neurodevelopmental and synaptic alterations in a human stem cell model of tuberous sclerosis. Cell Rep. 15, 86\u201395 (2016).","journal-title":"Cell Rep."},{"key":"37632_CR73","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1074\/mcp.RA117.000314","volume":"16","author":"R Bruderer","year":"2017","unstructured":"Bruderer, R. et al. Optimization of experimental parameters in data-independent mass spectrometry significantly increases depth and reproducibility of results*. Mol. Cell Proteom. 16, 2296\u20132309 (2017).","journal-title":"Mol. Cell Proteom."},{"key":"37632_CR74","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1073\/pnas.0811700106","volume":"106","author":"CS Ejsing","year":"2009","unstructured":"Ejsing, C. S. et al. Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry. Proc. Natl. Acad. Sci. 106, 2136\u20132141 (2009).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"37632_CR75","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1073\/pnas.1019267108","volume":"108","author":"JL Sampaio","year":"2011","unstructured":"Sampaio, J. L. et al. Membrane lipidome of an epithelial cell line. Proc. Natl. Acad. Sci. 108, 1903\u20131907 (2011).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"37632_CR76","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ejlt.201500145","volume":"117","author":"MA Surma","year":"2015","unstructured":"Surma, M. A. et al. An automated shotgun lipidomics platform for high throughput, comprehensive, and quantitative analysis of blood plasma intact lipids. Eur. J. Lipid Sci. Tech. 117, 1540\u20131549 (2015).","journal-title":"Eur. J. Lipid Sci. Tech."},{"key":"37632_CR77","first-page":"121","volume":"1761","author":"G Liebisch","year":"2006","unstructured":"Liebisch, G. et al. High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS\/MS). Biochim. Et. Biophys. Acta Bba - Mol. Cell Biol. Lipids 1761, 121\u2013128 (2006).","journal-title":"Biochim. Et. Biophys. Acta Bba - Mol. Cell Biol. Lipids"},{"key":"37632_CR78","doi-asserted-by":"publisher","first-page":"e29851","DOI":"10.1371\/journal.pone.0029851","volume":"7","author":"R Herzog","year":"2012","unstructured":"Herzog, R. et al. LipidXplorer: a software for consensual cross-platform lipidomics. Plos One 7, e29851 (2012).","journal-title":"Plos One"},{"key":"37632_CR79","doi-asserted-by":"publisher","first-page":"R8","DOI":"10.1186\/gb-2011-12-1-r8","volume":"12","author":"R Herzog","year":"2011","unstructured":"Herzog, R. et al. A novel informatics concept for high-throughput shotgun lipidomics based on the molecular fragmentation query language. Genome Biol. 12, R8\u2013R8 (2011).","journal-title":"Genome Biol."},{"key":"37632_CR80","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham, H. et al. Welcome to the Tidyverse. J. Open Source Softw. 4, 1686 (2019).","journal-title":"J. Open Source Softw."},{"key":"37632_CR81","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/bioinformatics\/btm069","volume":"23","author":"W Stacklies","year":"2007","unstructured":"Stacklies, W., Redestig, H., Scholz, M., Walther, D. & Selbig, J. pcaMethods a bioconductor package providing PCA methods for incomplete data. Bioinformatics 23, 1164\u20131167 (2007).","journal-title":"Bioinformatics"},{"key":"37632_CR82","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.3390\/ijms21134808","volume":"21","author":"S Gutbier","year":"2020","unstructured":"Gutbier, S. et al. Large-scale production of human ipsc-derived macrophages for drug screening. Int. J. Mol. Sci. 21, 4808 (2020).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37632-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37632-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37632-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T06:05:39Z","timestamp":1681279539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37632-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37632"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-37632-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1490073\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"1 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following authors have been employed at or collaborated with F. Hoffmann-La Roche AG while working on this project: Alexandra Gehrlein, Vinod Udayar, Nadia Anastasi, Martino Luca Morella, Iris Ruf, Doris Brugger, Sophia von der Mark, Ralf Thoma, Arne Rufer, Dominik Heer, Nina Pfahler, Anton Jochner, Jens Niewoehner, Luise Wolf, Matthias Fueth, Martin Ebeling, Roberto Villase\u00f1or, Yanping Zhu, Matthew C. Deen, Xiaoyang Shan, Zahra Ehsaei, Verdon Taylor, Ellen Sidransky, David J. Vocadlo, Per-Ola Freskg\u00e5rd, Ravi Jagasia. All authors declare no further competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Swiss research registry; BAG-hES-IMP-0031. UK Stem Cell Bank (UKSCB); Steering comm. appl. SCSC07-14.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"2057"}}